Cargando…

Effect of Silymarin as an Adjunct Therapy in Combination with Sofosbuvir and Ribavirin in Hepatitis C Patients: A Miniature Clinical Trial

Silymarin is proclaimed to be a blend of flavonolignans or phytochemicals. An era of new generation of direct-acting antivirals (DAAs) has commenced to have facet effect in swaying of the hepatitis C virus (HCV). Nonetheless, this therapy has serious side effects that jeopardize its efficacy. This s...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Sarfraz, Ullah, Najeeb, Parveen, Sadia, Javed, Ifra, Jalil, Nur Asyilla Che, Murtey, Mogana Das, Sheikh, Irfan Shahzad, Khan, Shahroz, Ojha, Suvash Chandra, Chen, Ke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828344/
https://www.ncbi.nlm.nih.gov/pubmed/35154575
http://dx.doi.org/10.1155/2022/9199190
_version_ 1784647823775498240
author Ahmed, Sarfraz
Ullah, Najeeb
Parveen, Sadia
Javed, Ifra
Jalil, Nur Asyilla Che
Murtey, Mogana Das
Sheikh, Irfan Shahzad
Khan, Shahroz
Ojha, Suvash Chandra
Chen, Ke
author_facet Ahmed, Sarfraz
Ullah, Najeeb
Parveen, Sadia
Javed, Ifra
Jalil, Nur Asyilla Che
Murtey, Mogana Das
Sheikh, Irfan Shahzad
Khan, Shahroz
Ojha, Suvash Chandra
Chen, Ke
author_sort Ahmed, Sarfraz
collection PubMed
description Silymarin is proclaimed to be a blend of flavonolignans or phytochemicals. An era of new generation of direct-acting antivirals (DAAs) has commenced to have facet effect in swaying of the hepatitis C virus (HCV). Nonetheless, this therapy has serious side effects that jeopardize its efficacy. This study is aimed at probing the effects of ribavirin (RBV) and sofosbuvir (SOF) along with silymarin as an adjunct therapy on hematological parameters and markers of obscured oxidative stress. The effect of DAAs along with silymarin was also examined on variable sex hormone level and liver function markers such as alanine aminotransferase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), and bilirubin. The study was followed to determine viral load and viral genotypes. A total of 30 patients were randomly divided into two equal groups comprising the control group (n = 15) and treatment group (n = 15). The control group was solely administered with DAAs (SOF and RBV; 400 mg/800 mg each/day). Conversely, the treatment group was dispensed with DAAs, but with adjunct therapy of silymarin (400 mg/day) along with DAAs (400/800 mg/day) over period of 8 weeks. Sampling of blood was performed at pre- and posttreatment levels for the evaluation of different propound parameters. Our data showed that silymarin adjunct therapy enhances the efficiency of DAAs. A decrease in menace level of liver markers such as ALT, ALP, AST, and bilirubin was observed (p > 0.05). The adjunct therapy concurrently also demonstrated an ameliorative effect on hematological indices and oxidative markers, for instance, SOD, TAS, GSH, GSSG, and MDA (p < 0.05), diminishing latent viral load. The silymarin administration was also found to revamp the fluster level of sex hormones. Our outcomes provide evidence that systematic administration of silymarin effectively remits deviant levels of hematological, serological, hormonal, and antioxidant markers. This demonstrates a possibly unique role of silymarin in mitigating hepatitis C.
format Online
Article
Text
id pubmed-8828344
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-88283442022-02-10 Effect of Silymarin as an Adjunct Therapy in Combination with Sofosbuvir and Ribavirin in Hepatitis C Patients: A Miniature Clinical Trial Ahmed, Sarfraz Ullah, Najeeb Parveen, Sadia Javed, Ifra Jalil, Nur Asyilla Che Murtey, Mogana Das Sheikh, Irfan Shahzad Khan, Shahroz Ojha, Suvash Chandra Chen, Ke Oxid Med Cell Longev Research Article Silymarin is proclaimed to be a blend of flavonolignans or phytochemicals. An era of new generation of direct-acting antivirals (DAAs) has commenced to have facet effect in swaying of the hepatitis C virus (HCV). Nonetheless, this therapy has serious side effects that jeopardize its efficacy. This study is aimed at probing the effects of ribavirin (RBV) and sofosbuvir (SOF) along with silymarin as an adjunct therapy on hematological parameters and markers of obscured oxidative stress. The effect of DAAs along with silymarin was also examined on variable sex hormone level and liver function markers such as alanine aminotransferase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), and bilirubin. The study was followed to determine viral load and viral genotypes. A total of 30 patients were randomly divided into two equal groups comprising the control group (n = 15) and treatment group (n = 15). The control group was solely administered with DAAs (SOF and RBV; 400 mg/800 mg each/day). Conversely, the treatment group was dispensed with DAAs, but with adjunct therapy of silymarin (400 mg/day) along with DAAs (400/800 mg/day) over period of 8 weeks. Sampling of blood was performed at pre- and posttreatment levels for the evaluation of different propound parameters. Our data showed that silymarin adjunct therapy enhances the efficiency of DAAs. A decrease in menace level of liver markers such as ALT, ALP, AST, and bilirubin was observed (p > 0.05). The adjunct therapy concurrently also demonstrated an ameliorative effect on hematological indices and oxidative markers, for instance, SOD, TAS, GSH, GSSG, and MDA (p < 0.05), diminishing latent viral load. The silymarin administration was also found to revamp the fluster level of sex hormones. Our outcomes provide evidence that systematic administration of silymarin effectively remits deviant levels of hematological, serological, hormonal, and antioxidant markers. This demonstrates a possibly unique role of silymarin in mitigating hepatitis C. Hindawi 2022-02-02 /pmc/articles/PMC8828344/ /pubmed/35154575 http://dx.doi.org/10.1155/2022/9199190 Text en Copyright © 2022 Sarfraz Ahmed et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ahmed, Sarfraz
Ullah, Najeeb
Parveen, Sadia
Javed, Ifra
Jalil, Nur Asyilla Che
Murtey, Mogana Das
Sheikh, Irfan Shahzad
Khan, Shahroz
Ojha, Suvash Chandra
Chen, Ke
Effect of Silymarin as an Adjunct Therapy in Combination with Sofosbuvir and Ribavirin in Hepatitis C Patients: A Miniature Clinical Trial
title Effect of Silymarin as an Adjunct Therapy in Combination with Sofosbuvir and Ribavirin in Hepatitis C Patients: A Miniature Clinical Trial
title_full Effect of Silymarin as an Adjunct Therapy in Combination with Sofosbuvir and Ribavirin in Hepatitis C Patients: A Miniature Clinical Trial
title_fullStr Effect of Silymarin as an Adjunct Therapy in Combination with Sofosbuvir and Ribavirin in Hepatitis C Patients: A Miniature Clinical Trial
title_full_unstemmed Effect of Silymarin as an Adjunct Therapy in Combination with Sofosbuvir and Ribavirin in Hepatitis C Patients: A Miniature Clinical Trial
title_short Effect of Silymarin as an Adjunct Therapy in Combination with Sofosbuvir and Ribavirin in Hepatitis C Patients: A Miniature Clinical Trial
title_sort effect of silymarin as an adjunct therapy in combination with sofosbuvir and ribavirin in hepatitis c patients: a miniature clinical trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828344/
https://www.ncbi.nlm.nih.gov/pubmed/35154575
http://dx.doi.org/10.1155/2022/9199190
work_keys_str_mv AT ahmedsarfraz effectofsilymarinasanadjuncttherapyincombinationwithsofosbuvirandribavirininhepatitiscpatientsaminiatureclinicaltrial
AT ullahnajeeb effectofsilymarinasanadjuncttherapyincombinationwithsofosbuvirandribavirininhepatitiscpatientsaminiatureclinicaltrial
AT parveensadia effectofsilymarinasanadjuncttherapyincombinationwithsofosbuvirandribavirininhepatitiscpatientsaminiatureclinicaltrial
AT javedifra effectofsilymarinasanadjuncttherapyincombinationwithsofosbuvirandribavirininhepatitiscpatientsaminiatureclinicaltrial
AT jalilnurasyillache effectofsilymarinasanadjuncttherapyincombinationwithsofosbuvirandribavirininhepatitiscpatientsaminiatureclinicaltrial
AT murteymoganadas effectofsilymarinasanadjuncttherapyincombinationwithsofosbuvirandribavirininhepatitiscpatientsaminiatureclinicaltrial
AT sheikhirfanshahzad effectofsilymarinasanadjuncttherapyincombinationwithsofosbuvirandribavirininhepatitiscpatientsaminiatureclinicaltrial
AT khanshahroz effectofsilymarinasanadjuncttherapyincombinationwithsofosbuvirandribavirininhepatitiscpatientsaminiatureclinicaltrial
AT ojhasuvashchandra effectofsilymarinasanadjuncttherapyincombinationwithsofosbuvirandribavirininhepatitiscpatientsaminiatureclinicaltrial
AT chenke effectofsilymarinasanadjuncttherapyincombinationwithsofosbuvirandribavirininhepatitiscpatientsaminiatureclinicaltrial